Asakura Keisuke

Dr. Asakura Keisuke

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
KMKyohei Masai
Kyohei Masai
HSHiroyuki Sakurai
Hiroyuki Sakurai
ASAoi Sukeda
Aoi Sukeda
SSShigeki Suzuki
Shigeki Suzuki
AKAsakura Keisuke
Asakura Keisuke
NHNobuyoshi Hiraoka
Nobuyoshi Hiraoka

1 May 2006 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MKMasafumi Kawamura
Masafumi Kawamura
YIYotaro Izumi
Yotaro Izumi
NTNorimasa Tsukada
Norimasa Tsukada
AKAsakura Keisuke
Asakura Keisuke
HSHiroaki Sugiura
Hiroaki Sugiura
KKKoichi Kobayashi
Koichi Kobayashi

19 March 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
AKAsakura Keisuke
Asakura Keisuke
TKTsukasa Kadota
Tsukasa Kadota
JMJuntaro Matsuzaki
Juntaro Matsuzaki
YYYukihiro Yoshida
Yukihiro Yoshida
YYYusuke Yamamoto
Yusuke Yamamoto
TOTakahiro Ochiya
Takahiro Ochiya
Lung cancer, the leading cause of cancer death worldwide, is most frequently detected through imaging tests. In this study, we investigated serum microRNAs (miRNAs) as a possible early screening tool for resectable lung cancer. First, we used serum samples from participants with and without lung cancer to comprehensively create 2588 miRNAs profiles; next, we established a diagnostic model based on the combined expression levels of two miRNAs (miR-1268b and miR-6075) in the discovery set (208 lung cancer patients and 208 non-cancer participants). The model displayed a sensitivity of 99% and specificity of 99% in the validation set (1358 patients and 1970 non-cancer participants) and exhibited high sensitivity regardless of histological type and pathological TNM stage of the cancer. Moreover, the diagnostic index markedly decreased after lung cancer resection. Thus, the model we developed has the potential to markedly improve screening for resectable lung cancer.

1 June 2017 in Lung Cancer
Verified
Journal Article
Open access
KTKenjiro Tsuruoka
Kenjiro Tsuruoka
HHHidehito Horinouchi
Hidehito Horinouchi
YGYasushi Goto
Yasushi Goto
SKShintaro Kanda
Shintaro Kanda
YFYutaka Fujiwara
Yutaka Fujiwara
YOYuichiro Ohe
Yuichiro Ohe
Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0-3]×stained area [0-100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Among the 227 patients included in this study, the patient demographics were as follows: median age (range), 65 years (19-84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV): 79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC): 46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as follows: TC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.

1 March 2012 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
MIMasanori Inoue
Masanori Inoue
SNSeishi Nakatsuka
Seishi Nakatsuka
HYHideki Yashiro
Hideki Yashiro
NINobutake Ito
Nobutake Ito
YIYotaro Izumi
Yotaro Izumi
SKSachio Kuribayashi
Sachio Kuribayashi

1 June 2013 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
HYHideki Yashiro
Hideki Yashiro
SNSeishi Nakatsuka
Seishi Nakatsuka
MIMasanori Inoue
Masanori Inoue
MKMasafumi Kawamura
Masafumi Kawamura
NTNorimasa Tsukada
Norimasa Tsukada
SKSachio Kuribayashi
Sachio Kuribayashi